These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11197207)

  • 21. Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.
    Marcelletti JF; Multani PS; Lancet JE; Baer MR; Sikic BI
    Leuk Res; 2009 Jun; 33(6):769-74. PubMed ID: 18976810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
    Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
    J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.
    Gerrard G; Payne E; Baker RJ; Jones DT; Potter M; Prentice HG; Ethell M; McCullough H; Burgess M; Mehta AB; Ganeshaguru K
    Haematologica; 2004 Jul; 89(7):782-90. PubMed ID: 15257929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
    Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
    Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.
    Massaad-Massade L; Ribrag V; Marie JP; Faussat AM; Bayle C; Dreyfus F; Gouyette A
    Anticancer Res; 1997; 17(6D):4647-51. PubMed ID: 9494583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
    Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
    Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
    Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
    Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia.
    Trnková Z; Bedrlíková R; Marková J; Michalová K; Stöckbauer P; Schwarz J
    Neoplasma; 2007; 54(5):383-90. PubMed ID: 17688368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
    Tóthová E; Elbertová A; Fricová M; Kafková A; Hlebasková M; Svorcová E; Stecová N; Guman T; Raffac S
    Neoplasma; 2001; 48(5):393-7. PubMed ID: 11845985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms.
    Li X; Li JP; Yuan HY; Gao X; Qu XJ; Xu WF; Tang W
    Methods Find Exp Clin Pharmacol; 2007 Nov; 29(9):607-17. PubMed ID: 18193112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance in haematological malignancies.
    Sonneveld P
    J Intern Med; 2000 May; 247(5):521-34. PubMed ID: 10809991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells.
    Holland ML; Panetta JA; Hoskins JM; Bebawy M; Roufogalis BD; Allen JD; Arnold JC
    Biochem Pharmacol; 2006 Apr; 71(8):1146-54. PubMed ID: 16458258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
    Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
    Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical significance of MDR-1 gene expression in the hemopoietic cells of patients with acute leukemias in different phases of the disease].
    Bykova TV; Sominskaia AA; Zaritskiĭ AIu; Stiuf IIu; Medvedeva BV; Anikina NA; Afanas'ev BV
    Ter Arkh; 1998; 70(7):11-4. PubMed ID: 9742628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug resistance in multiple myeloma.
    Sonneveld P; Lokhorst HM; Vossebeld P
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):34-9. PubMed ID: 9408959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.